<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405976</url>
  </required_header>
  <id_info>
    <org_study_id>PI080346</org_study_id>
    <nct_id>NCT01405976</nct_id>
  </id_info>
  <brief_title>Alternative of Treatment in Obesity Hypoventilation Syndrome</brief_title>
  <official_title>Mid-and Long-term Efficacy of Ventilation Non-invasive and Continuos Positive Airway Pressure in Obesity Hypoventilation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Española de Neumología y Cirugía Torácica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives: evaluate the efficacy of noninvasive ventilation (NIV) treatment versus
      continuous positive airway pressure (CPAP) and life style modification treatment in Obesity
      Hypoventilation Syndrome (OHS), with PCO2 (first phase) and days of hospitalization (second
      phase) analyzed as a primary variables and percentage of dropouts for medical reasons and
      mortality as operative variables. As secondary variables: Measure functional and clinical
      improvement during sleep and wakefulness, quality of life, echocardiography and the incidence
      and blood pressure and evolution of cardiovascular events. Objectives secondaries:role of
      apneogenic sleep events on molecular inflammation, endothelial damage and the genesis of
      diurnal hypercapnia. Methods:prospective, randomized controlled trial. Patients with OHS will
      be divided initially into two groups based on their apnea-hypopnea index (AHI) score, &gt;=30
      and &lt; 30, using conventional polysomnography. The AHI &gt;=30 group will be randomized to CPAP,
      NIV or life style modification treatments. The AHI &lt;=30 groups will be randomized to NIV or
      life style modification treatments. Treatment efficacy at the medium- and long-term will be
      analyzed by comparing groups. The role of apneic events and leptin in the genesis of daytime
      alveolar hypoventilation will be analyzed by comparing the daytime PCO2/AHI coefficient
      between responders and non-responders to CPAP treatment, and the evolution of leptin levels
      in the four branches of the study. The role of apneic events in metabolic and biochemical
      alterations and endothelial dysfunction will be analyzed by comparing basal and
      post-treatment levels of related substances between groups, with and without significant AHI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AHI &gt;=30 group will be analyzed to CPAP, NIV or life style modification treatments for
      two mouths.Once an evaluation is done during this period, the life style modification
      treatment will be randomized with the NIV/CPAP treatment for a continuation of three years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2009</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days of hospitalization</measure>
    <time_frame>at least three years</time_frame>
    <description>Days of hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PaCO2</measure>
    <time_frame>at the end of first two months</time_frame>
    <description>PaCO2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Dropouts for Medical reasons and mortality</measure>
    <time_frame>at least three years</time_frame>
    <description>Number of Dropouts for Medical reasons and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>two months and three years</time_frame>
    <description>quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory function</measure>
    <time_frame>two months and three years</time_frame>
    <description>respiratory function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>polysomnographic parameters</measure>
    <time_frame>two months</time_frame>
    <description>polysomnographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>molecular inflammation and endothelial dysfunction</measure>
    <time_frame>two months and three years</time_frame>
    <description>molecular inflammation and endothelial dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiographic parameters</measure>
    <time_frame>two months and three years</time_frame>
    <description>echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and new cardiovascular events</measure>
    <time_frame>three years</time_frame>
    <description>Blood pressure and new cardiovascular events</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>Obesity Hypoventilation Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIV for severe OSA group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CPAP for severe OSA group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Life stile modification for severe OSA group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIV for non-severe OSA group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Life stile modification for non-severe OSA group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>life style modification, noninvasive ventilation, CPAP</intervention_name>
    <description>life style modification, noninvasive ventilation, CPAP</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 15 and 80 years old.

          -  Absence of moderate or severe chronic obstructive pulmonary disease (COPD).

          -  Absence of neuromuscular, chest wall or metabolic disease which cause daytime
             hypercapnia.

          -  Absence of narcolepsy or restless legs syndrome

          -  Exceed correctly treatment of at least 30 minutes with CPAP/NIV at wakefulness.

        Exclusion Criteria:

          -  Psychophysical incapacity to answer questionnaires.

          -  Patients who are not able to be evaluated by means of quality of life questionnaires
             for suffering restrictive chronic disease previously diagnosed (neoplasy, chronic pain
             of any origin, renal failure, severe chronic obstructive pulmonary disease and any
             other restrictive chronic disease).

          -  Subjects with important chronic nasal obstruction that prevents from using CPAP/NIV.

          -  Informed consent not obtained.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan F Masa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Pedro de Alcántara. Cáceres. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara. Servicio Extremeño de Salud</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sociedad Española de Neumología y Cirugía Torácica</investigator_affiliation>
    <investigator_full_name>Juan F. Masa</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>sleep apneas</keyword>
  <keyword>noninvasive ventilation</keyword>
  <keyword>CPAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Obesity Hypoventilation Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

